Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00693212 · ClinicalTrials.gov registry record · Phase 3
Further Studies of Attention Deficit Disorder - Residual Type (RT)
A Phase 3 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 3
- Development phase
- 116
- Enrollment target
NCT00693212 is a Phase 3 study that has completed, run by University of Utah. The registered enrollment target is 116 participants.
The verdict
NCT00693212, a Phase 3 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 116 participants
- Enrollment target
Study Summary
The first phase was a double-blind crossover design of methylphenidate in the treatment of adult ADHD. The second phase consisted of an open-label extension trial of methylphenidate in adult ADHD. It was hypothesized that methylphenidate would prove more effective than placebo in treating ADHD symptoms during the first phase. It was also hypothesized that methylphenidate responders from the double-blind trial would continue to benefit from treatment in the second phase. Improvement would include both ADHD symptoms and social adjustment.
Interventions
- DRUG placebo
- DRUG methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 1986-02 |
| Est. Completion | 1994-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00693212
The ClinicalTrials.gov registry entry for NCT00693212 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00693212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00693212 about?
NCT00693212 is a clinical study titled "Further Studies of Attention Deficit Disorder - Residual Type (RT)". The first phase was a double-blind crossover design of methylphenidate in the treatment of adult ADHD. The second phase consisted of an open-label extension trial of methylphenidate in adult ADHD. It was hypothesized that methylphenidate would prove more effective than placebo in treating ADHD sympt...
What is the current status of trial NCT00693212?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 116 participants. The study started on 1986-02. Estimated completion is 1994-11.
What interventions are being tested in trial NCT00693212?
The interventions under investigation include: placebo (DRUG), methylphenidate (DRUG).
Who is sponsoring clinical trial NCT00693212?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.